Rituxan Access Solutions®—Connecting You to RITUXAN

At Genentech, we develop medicines for life-threatening medical conditions. We believe they should be accessible for the patients who need them.

Whether you have healthcare coverage or not, we can help you by:

  • Finding out if your healthcare plan pays for your medicine
  • Guiding you through the process of getting your medicine
  • Connecting you with our patient assistance programs

If you don't have a healthcare plan, you may be able to get your medicine for free.

To learn more about how we can help, contact us.

Cal 1-888-249-4918 to speak live with one of our Specialists.

You can also visit www.RituxanAccessSolutions.com.

 
 

Use the Rituxan
Access Solutions Navigator

Learn more about the programs available to help patients access the RITUXAN their doctors prescribe.

Start now

 
 

Contact Rituxan Access Solutions

The Genentech BioOncology Co-pay Card

 

At Genentech, we are committed to helping patients access the treatment they need. That's why we offer the Genentech BioOncology Co-pay Card. If you are eligible, this card can help lower the out-of-pocket costs like co-payments, co-insurance or deductibles for your Genentech cancer therapy.

  • Out-of-pocket costs are the part of your treatment that your healthcare plan requires you to pay. Check eligibility

This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.

Next Section Helpful Tools

Indications

RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent

People with serious infections should not receive RITUXAN.

Important Safety Information

  • RITUXAN can cause serious side effects that can lead to death, including infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
  • RITUXAN has also been associated with serious and life-threatening side effects, including the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
  • The most common side effects of RITUXAN seen in patients with non-Hodgkin's lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
  • Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including Medication Guide.

CVP=cyclophosphamide, vincristine, and prednisone or prednisolone; CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone.